BioCentury | Aug 18, 2020
Product Development

Unity outlines path forward for anti-aging programs after Phase II osteoarthritis failure

...Unity Biotechnology Inc. (NASDAQ:UBX) fell $8.28 (67%) to $4.15 on Monday after the San Francisco company reported that UBX0101...
...with moderate to severe painful osteoarthritis of the knee. It does not plan to advance UBX0101...
...case of osteoarthritis, Unity aimed to eliminate senescent cells by disrupting the p53 survival pathway with UBX0101...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

...demonstrate slowed disease progression via X-ray measurement of joint space narrowing. Unity’s most advanced candidate, UBX0101...
...not testing imaging endpoints in the trial, but may do so later. According to Leonard, UBX0101...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

...Biotechnology is going after a relatively unexplored mechanism for OA: cellular senescence. It’s lead compound, UBX0101...
...to eliminate the cells by disrupting the p53 survival pathway. In a Phase I trial, UBX0101...
BioCentury | May 4, 2018
Financial News

Unity prices $85M IPO

...31, 2016) . The company plans to begin a Phase I trial this quarter of UBX0101...
...C round in March (see BioCentury, March 23) . Unity Biotechnology Inc. (NASDAQ:UBX), Brisbane, Calif. Brian Moy UBX0101 UBX1967 Unity...
BioCentury | May 2, 2018
Financial News

Unity prices $85M IPO

...31, 2016) . The company plans to begin a Phase I trial this quarter of UBX0101...
...closed a $55 million series C round in March (see BioCentury Extra, March 19) . Brian Moy UBX0101 UBX1967 Unity...
BioCentury | Apr 13, 2018
Financial News

Unity proposes $85M IPO

...31, 2016) . The company plans to begin a Phase I study this half of UBX0101...
...2016) . Unity's investors also include China-based 6 Dimensions Capital. Unity Biotechnology Inc., Brisbane, Calif. Paul Bonanos UBX0101 Ascentage...
BioCentury | Apr 6, 2018
Financial News

Age-related disease play Unity planning IPO

...31, 2016) . The company plans to begin a Phase I study this half of UBX0101...
...see BioCentury Extra, April 25, 2016) . Unity's investors also include China-based 6 Dimensions Capital. Paul Bonanos UBX0101 UBX1967 Unity...
BioCentury | Mar 23, 2018
Financial News

Unity raises $55M series C

...lead candidates target senescent cells to treat age-related diseases (see BioCentury, Oct. 31, 2016 ). UBX0101...
...million in venture funding since its launch in 2011. Unity Biotechnology Inc., San Francisco, Calif. Virginia Li UBX0101 Unity...
BioCentury | Mar 19, 2018
Financial News

Unity raises $55M series C

...lead candidates target senescent cells to treat age-related diseases (see BioCentury, Oct. 31, 2016) . UBX0101...
...youth factors. Unity has raised $217 million in venture funding since its launch in 2011. Virginia Li UBX0101 Unity...
BioCentury | May 3, 2017
Distillery Therapeutics

Autoimmune disease

...OA). In patient-derived cultured human cartilage, a compound that induces apoptosis in senescent cells ( UBX0101...
...and IL-1β compared with vehicle. In a mouse model of post-traumatic OA, intra-articular injection of UBX0101...
...testing promoters of senescent cell clearance in additional animal models of age-related OA. Unity has UBX0101...
Items per page:
1 - 10 of 10